Meditation Intervention for the Treatment of Depression and Anxiety Symptoms in Patients Undergoing Dialysis: A Randomized Control Trial
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Depression
- Sponsor
- Lady Davis Institute
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Proportion of participants who enrolled who completed the 8 week-trial
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
This study examines the use of brief meditation interventions for patients with symptoms of anxiety and depression who are undergoing dialysis. Half of the participants will receive meditation interventions 3 times a week, while the other half will receive treatment as usual. This study will examine whether meditation is feasible and whether it has any effect on reducing symptoms of anxiety or depression.
Detailed Description
Roughly 50% of people who undergo dialysis experience stress, anxiety or depression, but often these conditions go undetected and untreated. It is known that meditation is helpful for anxiety and depression, especially in people who have chronic health conditions. This study will look specifically at meditation interventions tailored to the dialysis setting. Patients on maintenance hemodialysis with anxiety and depression will be recruited from hemodialysis units. Recruitment will start at the Jewish General Hospital in March 2016. Recruitment may later expand to University Health Network (Toronto), and/or other sites affiliated with McGill University or University of Toronto. Participants will then be randomly assigned to receive meditation or continue with their usual treatment. The participants assigned to the meditation group will practice several meditation techniques with a trained interventionist 3 times a week, during their dialysis sessions. At the end of the 8 weeks, the investigators will assess whether the meditation intervention was feasible (i.e. whether recruitment goals were met and drop out rates were as expected). Participants in the meditation group will be asked to rate whether they enjoyed the meditation on a scale. Both the participants assigned to the meditation group and to the usual treatment group will be asked to rate their depression and anxiety symptoms on the PHQ-9 and the GAD-7 scales to evaluate whether there was any change.
Investigators
Dr. Karl Looper
MD, FRCPC, Chief of the Department of Psychiatry, Jewish General Hospital
Lady Davis Institute
Eligibility Criteria
Inclusion Criteria
- •Patients currently receiving maintenance hemodialysis
- •Patients with depression and/or anxiety as indicated by scores of ≥10 on the Patient Health Questionnaire (PHQ-9) and/or General Anxiety Disorder-7 (GAD- 7)
- •Normal cognition or Mild Cognitive Impairment ("Normal" Result on the 3-minute Mini-Cog Test)
Exclusion Criteria
- •Mild, Moderate, or Severe Dementia ("Abnormal" Result on the 3-minute Mini-Cog Test)
- •Acute psychotic symptoms
- •Acute Suicidal ideation/intent
Outcomes
Primary Outcomes
Proportion of participants who enrolled who completed the 8 week-trial
Time Frame: 34 months
Tolerability of Meditation Intervention on a 10-point Likert scale
Time Frame: 8 weeks
Tolerability of intervention on a 10-point Likert scale
Proportion of participants screened as eligible who enroll
Time Frame: 34 months
Secondary Outcomes
- Change in General Anxiety Disorder-7 (GAD-7)(Baseline and at 8 weeks)
- Change in Patient Health Questionnaire (PHQ-9)(Baseline and at 8 weeks)